Technology | June 27, 2014

Mobius Medical Systems Receives FDA Clearance for Mobius3D Software

Mobius 3D Mobius Medical Systems LP FDA Clearance

June 27, 2014 — Mobius Medical Systems LP’s Mobius3D software has received U.S. market clearance as a Class II medical device from the U.S. Food and Drug Administration (FDA).

Mobius3D software is used for quality assurance (QA) and treatment plan verification in radiation therapy. It calculates 3-D radiation dose directly on a patient's computed tomography (CT) scan or a phantom. The calculation is based on treatment plans initially calculated by a planning system. The MobiusFX module allows users to perform calculations based on linac delivery log data.

Mobius3D is the first software to verify patient plans in 3-D using an independently developed TPS quality algorithm. Mobius3D works with all major linear accelerators, offering a streamlined workflow. Mobius3D makes patient plan QA faster and easier while supplying details not available from basic meaningful use verification software.

The FDA clearance includes MobiusFX, an optional add-on that utilizes the same independently developed collapsed-cone algorithm with delivery log files to determine 3-D dose delivered to the patient. MobiusFX provides clinicians a new and better way to perform patient-specific QA. Current methods that rely on ion chamber or diode arrays, EPIDs, or film are excessively time consuming, taking anywhere from 30 to 90 minutes per patient to complete and analyze. The long time required often necessitates the need for clinicians to work after hours or weekends in order to accomplish this important QA task. MobiusFX only requires enough time to deliver the beams. This allows QA to be easily achieved during breaks between patients or over a lunch hour, offering an opportunity to reclaim those nights and weekends.

As a true 3-D solution for patient plan and delivery QA, Mobius3D and MobiusFX can provide information that is not available from traditional methods. Customizable DVH objectives, that include RTOG protocols and Task Group 101 recommendations by default, can be used by Mobius3D to tell clinicians if their treatments are meeting goals. MobiusFX compares data from the machine delivery to expected positions from the TPS plan. This provides users confidence that all parameters were delivered exactly as prescribed. Moreover, MobiusFX will extend the IMRT QA process from a pre-treatment check into per-fraction verifications. Lastly, Mobius3D’s intuitive browser-based interface can be accessed with any computer, tablet, or smartphone, making it extremely easy to evaluate results.

For more information: www.mobiusmed.com

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init